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Post-hospital evaluation for the cause of ischemic stroke has gained increased attention in the last decade, particularly 
the search for paroxysmal atrial fibrillation. Initial studies of 
Holter monitoring documented rates of atrial fibrillation of 
≈5% or 1 in 20 patients.1 Further, prolonged monitoring for 
as long as 1 week appeared to increase detection rates, with 
a range of 5.7% to 7.7%.1 When devices became available to 
increase monitoring ≤21 days, detection rates over 20% were 
documented.2 A 2014 systematic review of detection of atrial 
fibrillation after stroke found an overall rate of detection of 
11.5%; however, detection rates varied based on patient selec-
tion, device selected, timing of device placement, duration 
of monitoring, and diagnostic criteria for paroxysmal atrial 
fibrillation.3 Two randomized trials of prolonged monitoring 
after ischemic stroke, both published after the 2014 system-
atic review, found higher rates of atrial fibrillation with longer 
duration of monitoring. The 30-Day Cardiac Event Monitor 
Belt for Recording Atrial Fibrillation after a Cerebral Ischemic 
Event (EMBRACE) trial found a 90-day rate of 16.1% in 
patients undergoing 30 consecutive days of monitoring versus 
3.2% of patients undergoing 24 hours of monitoring.4 In the 
Cryptogenic Stroke and Underlying AF (CRYSTAL AF) trial, 
the 6-month rate was 8.9% in patients who had an implanted 
cardiac monitor versus 1.4% in patients who had routine evalu-
ation. The lower rates of detection in CRYSTAL-AF compared 
with EMBRACE may have been attributable to a younger 
cohort of patients being evaluated; the mean age was 61.5 years 
in CRYSTAL-AF and 72.9 years in EMBRACE. In both trials, 
there was incremental detection of atrial fibrillation episodes 
over time, that is, new atrial fibrillation was identified continu-
ously over time in both studies.5 EMBRACE followed a small 
number of patients out to 3 years; the rate of atrial fibrillation 
was 30% in those with the implanted cardiac monitor and 3% 
in those who had routine monitoring.
In most studies, the minimum duration of atrial fibrilla-
tion that is considered clinically important is 30 seconds 
and a criterion for meeting an end point. According to the 
American Heart Association and American College of 
Cardiology guidelines, the definition of paroxysmal atrial 
fibrillation is an episode lasting <7 days;6 however, the 
minimum duration that is clinically important has not been 
absolutely defined. By convention, a continuous rhythm of 
30 seconds has been considered clinically important though 
AHA guidelines from 2006 acknowledged that “episodes of 
atrial fibrillation briefer than 30 seconds may be important 
in certain clinical situations involving symptomatic patients, 
preexcitation or in assessing the effectiveness of therapeutic 
interventions.”7 The 2014 guidelines do not describe a mini-
mum duration.6 Future research will be required to deter-
mine whether episodes <30 seconds are associated with a 
greater stroke risk in affected individuals.
Concomitant with the interest in monitoring for atrial fibril-
lation poststroke, there has also been interest in predicting 
which patients are most likely to have atrial fibrillation dur-
ing outpatient evaluation. A potential goal of this work would 
be to identify those at highest risk and target monitoring and 
treatment strategies. Risk scores have been proposed to iden-
tify these patients; however, these scoring systems have not 
been widely adopted because of relatively low sensitivities 
and specificities.8–10 In this issue of Stroke, Favilla and col-
leagues sought to determine clinical and paraclinical features 
that best predicted the risk of future detection of atrial fibril-
lation, defined, in contrast to EMBRACE and CRSYTAL-AF, 
as episodes of any duration.11 The overall detection rate was 
14%; of these patients, 42% had episodes lasting <30 seconds. 
The mean age in this cohort was 62.9 years. In the multivari-
able analysis, age >60 years and prior cortical or cerebellar 
infarction were predictors of detecting atrial fibrillation. When 
both features were present, 33% of these patients were later 
identified as having atrial fibrillation. When neither feature 
was present, 4% were later identified as having atrial fibrilla-
tion. Notably, factors that had previously been associated with 
atrial fibrillation in other studies, such as atrial size, were not 
significantly associated with atrial fibrillation in this study. 
Though these findings require validation in an independent 
cohort, they are nonetheless intriguing and may represent a 
tool in settings with limited resources. A 2010 United States–
based cost-effectiveness study of outpatient cardiac monitor-
ing in patients with cryptogenic stroke suggested that even 
with detection rates as low as 4%, the cost-utility ratio was 
$13 000 per quality-adjusted life-year gained.12 Interventions 
with cost-utility ratios <$50 000 per quality-adjusted life-year 
gained are generally considered worthwhile and argue in favor 
of universal application of outpatient cardiac monitoring in 
patients with cryptogenic stroke. Therefore, in settings which 
are not as resource-constrained, a prognostication tool may 
not be as valuable.
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Whether atrial fibrillation detected after ischemic stroke 
is the cause or result of the event or simply an event that 
occurred independently requires further study. Some reports 
suggest that infarctions in certain brain locations, such as the 
insula, increase the chance of finding atrial fibrillation;13,14 
however, that was not the case in the current study by Favilla 
and colleagues nor in the EMBRACE trial.15 Further analy-
sis of the CRYSTAL-AF data is ongoing.16 Having data on 
the rate of atrial fibrillation in age and sex-matched controls 
without any history of stroke, those with intracerebral hem-
orrhage, and those with other nonstroke brain injury might 
shed light on whether atrial fibrillation detected after isch-
emic stroke truly occurs at an increased rate.
An important question is the therapeutic consequence 
once occult paroxysmal atrial fibrillation has been detected 
in patients with stroke. Certainly, other potential causes 
of stroke should be carefully evaluated in the absence of a 
direct cause–effect relationship. Moreover, oral anticoagu-
lation with either vitamin K antagonists or non-vitamin K 
oral anticoagulants is recommended to prevent thromboem-
bolism among patients with clinically apparent nonvalvular 
atrial fibrillation and a CHA2DS2-VASc (combined stroke 
risk score: congestive heart failure, hypertension, age ≥75 
years, diabetes, prior stroke/transient ischemic attack, vas-
cular disease, sex) score of >1.17 However, it remains to be 
shown whether long-term oral anticoagulation provides a 
reasonable balance of safety and efficacy among patients 
with cryptogenic stroke and occult paroxysmal atrial fibril-
lation, particularly among young patients (<60 years of 
age) with structurally normal hearts. In this context, ongo-
ing trials, such as RESPECT-ESUS (Dabigatran Etexilate 
for Secondary Stroke Prevention in Patients With Embolic 
Stroke of Undetermined Source)18 and NAVIGATE ESUS 
(Rivaroxaban Versus Aspirin in Secondary Prevention of 
Stroke and Prevention of Systemic Embolism in Patients 
With Recent Embolic Stroke of Undetermined Source),19 
are randomizing patients with cryptogenic stroke to aspi-
rin or one of the newer oral anticoagulants. If indeed 10% 
to 20% of these patients have underlying paroxysmal atrial 
fibrillation as the cause of their stroke and there is a sta-
tistically significant advantage to anticoagulation over anti-
platelet therapy in this group of patients, prediction models 
and long-term cardiac monitoring may become a moot point. 
Nevertheless, patients with cryptogenic stroke who continue 
to have strokes despite anticoagulation may be those who 
are targeted for long-term monitoring. If paroxysmal atrial 
fibrillation is identified in patients refractory to anticoagu-
lation, other methods of treating atrial fibrillation, such as 
atrial appendage occlusion, atrial appendage ligation, and 
pulmonary artery ablation, may be considered.
In summary, atrial fibrillation is increasingly being identi-
fied in patients with cryptogenic stroke. Longer duration of 
cardiac monitoring results in higher detection rates. Whether 
all the episodes detected, particularly brief ones, are clinically 
relevant requires further study. Further, whether episodes of 
atrial fibrillation detected after stroke is a result rather than the 
cause of stroke also merits additional investigation. Clinical 
prognostication tools may be beneficial, especially in settings 
where resources, such as cardiac outpatient monitors, are 
limited. Ongoing trials of non-vitamin K oral anticoagulants 
in the setting of cryptogenic stroke are of particular interest; if 
positive, that might limit the need for outpatient cardiac moni-
toring or prognostication tools.
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